Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.63 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL9766065 | 0.99 | SIGMAR1 (0.62) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL10784053 | 0.79 | HTR1A (0.65) | SIGMAR1HTR1ADRD2 | |
| SCHEMBL9765986 | 0.78 | SIGMAR1 (0.61) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL9766082 | 0.78 | SIGMAR1 (1.00) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL10435228 | 0.78 | SIGMAR1 (1.00) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL7521159 | 0.77 | SIGMAR1 (0.66) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL30350966 | 0.77 | SIGMAR1 (0.66) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL11841456 | 0.76 | SIGMAR1 (0.50) | SIGMAR1CYP1A2 | |
| SCHEMBL10787481 | 0.76 | HTR1A (0.62) | SIGMAR1HTR1ADRD2 | |
| SCHEMBL7855443 | 0.76 | SIGMAR1 (0.63) | SIGMAR1HTR1AKDM4ECYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4994460-A | Treatment or prevention of disorders resulting from central nervous system anoxia | BRISTOL-MYERS SQUIBB CO. (US) | 1991-02-19 | — | — | US | claimed |
| EP-0400661-A1 | Agents for treatment of brain ischemia | Bristol-Myers Squibb Company (US) | 1990-12-05 | — | — | EP | claimed |